DF-1001
Dragonfly
['breast', 'nsclc', 'sclc']
in this phase 1 study, df1001 was safe and well tolerated as monotherapy, with promising efficacy associated with immune infiltration and activation in tumors of heavily pretreated patients with both her2-low &amp; her2-high expressing breast cancers &amp; nsclc #asco23
We are a clinical-stage company developing drugs targeting natural killer cells & other cells of the innate immune system, to eliminate cancer & other diseases.